{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T04:17:41Z","timestamp":1729657061100,"version":"3.28.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,22]]},"DOI":"10.7759\/cureus.72092","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T08:36:57Z","timestamp":1729586217000},"source":"Crossref","is-referenced-by-count":0,"title":["An Analysis of Cost Variation Among Drugs Available in the Indian Market for the Treatment of Chronic Bone-Related Ailments"],"prefix":"10.7759","author":[{"given":"Mamatha","family":"Jayachandran","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikku M","family":"Geevarughese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Princy  L","family":"Palatty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjeshwar Poonam","family":"Baliga-Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dhanya","family":"Sacheendran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manjeshwar S","family":"Baliga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1590\/0037-8682-0285-2021","article-title":"The burden of low back pain, rheumatoid arthritis, osteoarthritis, and gout and their respective attributable risk factors in Brazil: results of the GBD 2017 study","volume":"55","author":"Wolf J","year":"2022","unstructured":"Wolf J, Fran\u00e7a EB, Assun\u00e7\u00e3o A\u00c1. The burden of low back pain, rheumatoid arthritis, osteoarthritis, and gout and their respective attributable risk factors in Brazil: results of the GBD 2017 study. Rev Soc Bras Med Trop. 2022, 55:e0285. 10.1590\/0037-8682-0285-2021","journal-title":"Rev Soc Bras Med Trop"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00163-7","article-title":"Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021","volume":"5","author":"GBD 2021 Osteoarthritis Collaborators","year":"2023","unstructured":"GBD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990-2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023, 5:e508-22. 10.1016\/S2665-9913(23)00163-7","journal-title":"Lancet Rheumatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-062183","article-title":"Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study","volume":"12","author":"Liu S","year":"2022","unstructured":"Liu S, Wang B, Fan S, Wang Y, Zhan Y, Ye D. Global burden of musculoskeletal disorders and attributable factors in 204 countries and territories: a secondary analysis of the Global Burden of Disease 2019 study. BMJ Open. 2022, 12:e062183. 10.1136\/bmjopen-2022-062183","journal-title":"BMJ Open"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(23)00098-X","article-title":"Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021","volume":"5","author":"GBD 2021 Low Back Pain Collaborators","year":"2023","unstructured":"GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023, 5:e316-29. 10.1016\/S2665-9913(23)00098-X","journal-title":"Lancet Rheumatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020, 396:1204-22. 10.1016\/S0140-6736(20)30925-9","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwp356","article-title":"The association between obesity and low back pain: a meta-analysis","volume":"171","author":"Shiri R","year":"2010","unstructured":"Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The association between obesity and low back pain: a meta-analysis. Am J Epidemiol. 2010, 171:135-54. 10.1093\/aje\/kwp356","journal-title":"Am J Epidemiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.06.002","article-title":"Osteoarthritis and its management - Epidemiology, nutritional aspects and environmental factors","volume":"17","author":"Bortoluzzi A","year":"2018","unstructured":"Bortoluzzi A, Furini F, Scir\u00e8 CA. Osteoarthritis and its management - Epidemiology, nutritional aspects and environmental factors. Autoimmun Rev. 2018, 17:1097-104. 10.1016\/j.autrev.2018.06.002","journal-title":"Autoimmun Rev"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-789X.2006.00251.x","article-title":"Musculoskeletal disorders associated with obesity: a biomechanical perspective","volume":"7","author":"Wearing SC","year":"2006","unstructured":"Wearing SC, Hennig EM, Byrne NM, Steele JR, Hills AP. Musculoskeletal disorders associated with obesity: a biomechanical perspective. Obes Rev. 2006, 7:239-50. 10.1111\/j.1467-789X.2006.00251.x","journal-title":"Obes Rev"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215920","article-title":"Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017","volume":"78","author":"Safiri S","year":"2019","unstructured":"Safiri S, Kolahi AA, Hoy D, et al.. Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019, 78:1463-71. 10.1136\/annrheumdis-2019-215920","journal-title":"Ann Rheum Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker299","article-title":"Modifiable risk factors for RA: prevention, better than cure?","volume":"51","author":"Lahiri M","year":"2012","unstructured":"Lahiri M, Morgan C, Symmons DP, Bruce IN. Modifiable risk factors for RA: prevention, better than cure?. Rheumatol (Oxford). 2012, 51:499-512. 10.1093\/rheumatology\/ker299","journal-title":"Rheumatol (Oxford)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez476","article-title":"Global, regional and national burden of gout, 1990-2017: a systematic analysis of the Global Burden of Disease Study","volume":"59","author":"Xia Y","year":"2020","unstructured":"Xia Y, Wu Q, Wang H, et al.. Global, regional and national burden of gout, 1990-2017: a systematic analysis of the Global Burden of Disease Study. Rheumatology (Oxford). 2020, 59:1529-38. 10.1093\/rheumatology\/kez476","journal-title":"Rheumatology (Oxford)"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s13018-021-02821-8","article-title":"Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis","volume":"16","author":"Salari N","year":"2021","unstructured":"Salari N, Darvishi N, Bartina Y, et al.. Global prevalence of osteoporosis among the world older adults: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021, 16:669. 10.1186\/s13018-021-02821-8","journal-title":"J Orthop Surg Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-023-1971-4","article-title":"Sex specific global burden of osteoporosis in 204 countries and territories, from 1990 to 2030: an age-period-cohort modeling study","volume":"27","author":"Zhu Z","year":"2023","unstructured":"Zhu Z, Yu P, Wu Y, et al.. Sex specific global burden of osteoporosis in 204 countries and territories, from 1990 to 2030: an age-period-cohort modeling study. J Nutr Health Aging. 2023, 27:767-74. 10.1007\/s12603-023-1971-4","journal-title":"J Nutr Health Aging"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/IPRP.S108047","article-title":"Role of the pharmacist in reducing healthcare costs: current insights","volume":"6","author":"Dalton K","year":"2017","unstructured":"Dalton K, Byrne S. Role of the pharmacist in reducing healthcare costs: current insights. Integr Pharm Res Pract. 2017, 6:37-46. 10.2147\/IPRP.S108047","journal-title":"Integr Pharm Res Pract"},{"key":"ref15","article-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","author":"U.S. Department of Health and Human Services","year":"2004","unstructured":"U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. U.S. Department of Health and Human Services, Office of the Surgeon General, Rockville, MD; 2004."},{"key":"ref16","unstructured":"Pharmaceutical and medical devices bureau of India (PMBI), government of India. (2024). Accessed. September 17, 2024: https:\/\/janaushadhi.gov.in\/ProductList.aspx."},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S19801","article-title":"Adherence and health care costs","volume":"7","author":"Iuga AO","year":"2014","unstructured":"Iuga AO, McGuire MJ. Adherence and health care costs. Risk Manag Healthc Policy. 2014, 7:35-44. 10.2147\/RMHP.S19801","journal-title":"Risk Manag Healthc Policy"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2015.11.005","article-title":"Importance of economic evaluation in health care: an Indian perspective","volume":"9","author":"Dang A","year":"2016","unstructured":"Dang A, Likhar N, Alok U. Importance of economic evaluation in health care: an Indian perspective. Value Health Reg Issues. 2016, 9:78-83. 10.1016\/j.vhri.2015.11.005","journal-title":"Value Health Reg Issues"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2023.2194507","article-title":"Implementation of equity and access in Indian healthcare: current scenario and way forward","volume":"11","author":"Ghia C","year":"2023","unstructured":"Ghia C, Rambhad G. Implementation of equity and access in Indian healthcare: current scenario and way forward. J Mark Access Health Policy. 2023, 11:2194507. 10.1080\/20016689.2023.2194507","journal-title":"J Mark Access Health Policy"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-005-0807-6","article-title":"A validation study of the WHO analgesic ladder: a two-step vs three-step strategy","volume":"13","author":"Maltoni M","year":"2005","unstructured":"Maltoni M, Scarpi E, Modonesi C, et al.. A validation study of the WHO analgesic ladder: a two-step vs three-step strategy. Support Care Cancer. 2005, 13:888-94. 10.1007\/s00520-005-0807-6","journal-title":"Support Care Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.4103\/jfmpc.jfmpc_1737_23","article-title":"A study on the price variability of branded medicines and Jan aushadi versions of selected commonly prescribed psychiatric medications in India using a cost-comparative approach and a passive evaluation of the Jan aushadhi scheme in India","volume":"13","author":"Vasisht PV","year":"2024","unstructured":"Vasisht PV. A study on the price variability of branded medicines and Jan aushadi versions of selected commonly prescribed psychiatric medications in India using a cost-comparative approach and a passive evaluation of the Jan aushadhi scheme in India. J Family Med Prim Care. 2024, 13:2054-9. 10.4103\/jfmpc.jfmpc_1737_23","journal-title":"J Family Med Prim Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2018.02.019","article-title":"A cost analysis of the psychotropic medicines sold in the jan aushadhi generic drug stores in India","volume":"33","author":"Uvais NA","year":"2018","unstructured":"Uvais NA. A cost analysis of the psychotropic medicines sold in the jan aushadhi generic drug stores in India. Asian J Psychiatr. 2018, 33:40-1. 10.1016\/j.ajp.2018.02.019","journal-title":"Asian J Psychiatr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.19231","article-title":"Generic anticancer drugs of the Jan Aushadhi scheme in India and their branded counterparts: the first cost comparison study","volume":"13","author":"George T","year":"2021","unstructured":"George T, Baliga MS. Generic anticancer drugs of the Jan Aushadhi scheme in India and their branded counterparts: the first cost comparison study. Cureus. 2021, 13:e19231. 10.7759\/cureus.19231","journal-title":"Cureus"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-023-03753-x","article-title":"Pharmacoeconomic appraisal of treating head and neck cancer with various chemotherapy and chemoirradiation regimens using branded and Jan-aushadhi drugs in India","volume":"75","author":"Krishna A","year":"2023","unstructured":"Krishna A, Jayachandran M, Sacheendran D, George T, Palatty PL, Baliga MS. Pharmacoeconomic appraisal of treating head and neck cancer with various chemotherapy and chemoirradiation regimens using branded and Jan-aushadhi drugs in India. Indian J Otolaryngol Head Neck Surg. 2023, 75:1782-91. 10.1007\/s12070-023-03753-x","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1080\/14737167.2019.1637735","article-title":"Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India","volume":"20","author":"Kashyap A","year":"2020","unstructured":"Kashyap A, Balaji MN, Chhabra M, Rashid M, Muragundi PM. Cost analysis of various branded versus generic chemotherapeutic agents used for the treatment of early breast cancer- a deep insight from India. Expert Rev Pharmacoecon Outcomes Res. 2020, 20:355-61. 10.1080\/14737167.2019.1637735","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1055\/s-0044-1779721","article-title":"Pharmacoeconomic analysis of treating lung cancer with different regimens using the cheapest and costliest brand and the generic Jan aushadhi drugs marketed in India","volume":"45","author":"Krishna A","year":"2024","unstructured":"Krishna A, Palatty PL, George T, Baliga MS. Pharmacoeconomic analysis of treating lung cancer with different regimens using the cheapest and costliest brand and the generic Jan aushadhi drugs marketed in India. Indian J Med Paediatr Oncol. 2024, 45:176-82. 10.1055\/s-0044-1779721","journal-title":"Indian J Med Paediatr Oncol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102303","article-title":"Health economics and effectiveness analysis of generic anti-diabetic medication from jan aushadhi: An ambispective study in community pharmacy","volume":"15","author":"Chaudhary RK","year":"2021","unstructured":"Chaudhary RK, Philip MJ, Santhosh A, Karoli SS, Bhandari R, Ganachari MS. Health economics and effectiveness analysis of generic anti-diabetic medication from jan aushadhi: An ambispective study in community pharmacy. Diabetes Metab Syndr. 2021, 15:102303. 10.1016\/j.dsx.2021.102303","journal-title":"Diabetes Metab Syndr"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.7964","article-title":"A cost variation analysis of drugs available in the Indian market for the management of thromboembolic disorders","volume":"12","author":"Ray A","year":"2020","unstructured":"Ray A, Najmi A, Khandelwal G, Sadasivam B. A cost variation analysis of drugs available in the Indian market for the management of thromboembolic disorders. Cureus. 2020, 12:e7964. 10.7759\/cureus.7964","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/298978-an-analysis-of-cost-variation-among-drugs-available-in-the-indian-market-for-the-treatment-of-chronic-bone-related-ailments","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T08:36:59Z","timestamp":1729586219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/298978-an-analysis-of-cost-variation-among-drugs-available-in-the-indian-market-for-the-treatment-of-chronic-bone-related-ailments"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":28,"URL":"https:\/\/doi.org\/10.7759\/cureus.72092","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,22]]}}}